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Myofibroblasts are stromal cells mainly involved in tissue repair. These cells present
contractile properties and play a major role in extracellular matrix deposition and
remodeling. In liver, myofibroblasts are found in two critical situations. First, during fetal
liver development, especially in portal tracts, myofibroblasts surround vessels and bile
ducts during their maturation. After complete development of the liver, myofibroblasts
disappear and are replaced in portal tracts by portal fibroblasts. Second, during liver
injury, myofibroblasts re-appear principally deriving from the activation of local stromal
cells such as portal fibroblasts and hepatic stellate cells or can sometimes emerge by an
epithelial-mesenchymal transition process. After acute injury, myofibroblasts play also a
major role during liver regeneration. While myofibroblastic precursor cells are well known,
the spectrum of activation and the fate of myofibroblasts during disease evolution are not
fully understood. Some data are in accordance with a possible deactivation, at least
partial, or a disappearance by apoptosis. Despite these shadows, liver is definitively
a pertinent model showing that myofibroblasts are pivotal cells for extracellular matrix
control during morphogenesis, repair and fibrous scarring.
Keywords: portal fibroblast, myofibroblast, hepatic stellate cell, alpha-smooth muscle actin, liver development,
fibrosis, tumoral stroma
Introduction
In homeostatic state, myofibroblasts are absent from the normal adult liver. Myofibroblasts are
stromal cells showing myoid features and involved in production or remodeling of the extracellular
matrix (ECM) scaffold. Myofibroblasts are recruited from the transdifferentiation of local stromal
cells. Historically, in the liver, it has been postulated that the hepatic stellate cell, also named Ito
cell or lipocyte, was the provider of myofibroblasts: in this logic, myofibroblasts were called also
transitional cells, activated stellate cells or myofibroblastic cells (French et al., 1988;Mak and Lieber,
1988; Bachem et al., 1989). But other studies have shown afterwards, that fibroblasts located in the
connective tissue of the portal tracts are important providers of myofibroblasts (Tang et al., 1994;
Tuchweber et al., 1996). This implication of portal fibroblasts as precursor cells of myofibroblasts
was observed in human obstructive biliary diseases as well as in animal models (Desmoulière, 2007;
Wells, 2014). Indeed, portal fibroblasts are involved as hepatic stellate cells in liver repair after injury
Abbreviations: SM, smooth muscle; ECM, extracellular matrix; WD, week of development; CCl4, carbon tetrachloride; EMT,
epithelial-mesenchymal transition.
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and in tumoral reaction. Portal fibroblasts are also an important
stromal cell playing a major role during the fetal liver
morphogenesis.
Myofibroblast Definition
Since their first description in granulation tissue (Gabbiani
et al., 1971), numerous studies have been published leading to
remarkable progresses in the understanding of myofibroblast
biological characteristics and of their participation in
physiological and pathological situations (Hinz et al., 2012).
Myofibroblasts exert traction forces by expressing α-smooth
muscle (SM) actin and are able to participate in connective
tissue remodeling by synthesizing ECM components, matrix
metalloproteinases and their inhibitors. When the repair process
is completed, in normal situations, myofibroblasts disappear
by apoptosis (Desmoulière et al., 1995). Although presenting
SM cell features, myofibroblasts however do not express h-
caldesmon (150 kDa caldesmon) and smoothelin which seem to
be specific for SM differentiation last step (Frid et al., 1992; van
der Loop et al., 1997; Ceballos et al., 2000).
Liver Myofibroblast during Liver
Morphogenesis
Liver mesenchyme deriving from the mesoblast of the septum
transversum is invaded by the epithelial part of the entodermal
hepatic diverticulum during the 4th week of development (WD)
of normal human embryo (Roskams and Desmet, 2008). The
lobulation of the fetal liver begins near the liver hilum at the
9th WD, and continues with a centrifugal pattern in the liver
FIGURE 1 | Expression of α-smooth muscle actin (A,B,C) and of
h-caldesmon (D,E,F) in fetal liver tissues during the lobulation of the
fetal liver. α-Smooth muscle (SM) actin is expressed by myofibroblasts while
h-caldesmon is expressed by SM cells. The lobulation of the fetal liver begins
near the liver hilum at the 9th week of development, and continues with a
centrifugal pattern in the liver until about 1 month post-partum. Three stages
of the portal tract maturation are described. At the ductal plate stage, the
portal vein is surrounded by myofibroblasts that express α-SM actin (A); SM
cells expressing h-caldesmon are not yet present (D). At the ductal plate
remodeling stage, α-SM actin expressing myofibroblasts surround the biliary
tubular structures from the ductal plate, which were incorporated in the portal
stroma (B); again, h-caldesmon is not still present (E). At the remodeled
stage, α-SM actin expressing myofibroblasts disappear; only arterial tunica
media SM cells expressed both α-SM actin (C) and h-caldesmon (F).
until about 1 month post-partum. Mesenchymal part of the
liver gives birth to the sinusoid and perisinusoidal space in the
future lobules and future portal tracts at the edge of the lobules,
including finally portal fibroblasts (Asahina et al., 2011). Each
mesenchymal compartment shows a specific maturation pattern
(Figure 1).
- The portal tract maturation follows a sequence classically
divided in three stages. At the first stage, the ductal plate
stage, a mesenchymal future portal tract containing a large
branch of portal vein and limited stroma is surrounded by
segments of double-layered cylindrical or tubular structures. At
the second stage, the ductal plate remodeling stage, the future
portal tract incorporates the tubular structures into the stroma
and branches of hepatic artery develop. At the last stage, the
remodeled stage, the portal tract is mature and is characterized
by a normal connective tissue containing a branch of portal
vein, two branches of the hepatic artery and two bile ducts
(Crawford et al., 1998).
- The mesenchyme of the septum transversum framework
gives rise to sinusoidal compartment, which comprises
endothelial and mesenchymal cells entrapped in the
perisinusoidal space (future Disse’s space). Endothelium
of the sinusoid is continuous in the beginning of development
and discontinuous after the 12th WD (Enzan et al., 1997).
Perisinusoidal mesenchymal cells contain the developing
hepatic stellate cells (Wake, 2006), which the embryonic origin
is controversial (for review, see Geerts, 2004).
Other mesenchymal cells in the septum transversum can
differentiate into fibroblasts, which occupy the subcapsular
connective tissue of the liver (Enzan et al., 1997).
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Stromal cells with myoid features, called myofibroblasts
by Libbrecht et al. (2002), are specially implicated in the
maturation of the future portal tract (Villeneuve et al., 2009).
During the first stage, future portal tract stroma contains
myofibroblasts, which surround also portal vein branch. At the
second stage, myofibroblasts surround developing bile ducts,
developing arterial branches and portal vein. Outside these
areas, portal myofibroblasts give place to fibroblastic cells, which
do not express α-SM actin. During the maturation of the
arterial branches, the tunica media myofibroblasts are replaced
by SM cells, which express h-caldesmon. At the last stage,
myofibroblasts have disappeared from the portal tract. On these
morphological data, we suggest as other a potential role of
the portal myofibroblasts during the maturation of biliary tree
(Libbrecht et al., 2002; Villeneuve et al., 2009).
Quite the opposite, myofibroblasts are poorly implicated in
perisinusoidal maturation. Numerous cellular retinol-binding
protein-1 positive hepatic stellate cells extend cytoplasmic
processes from the 13th WD, but only few of them also express
α-SM actin (Geerts, 2001; Villeneuve et al., 2009).
Liver Myofibroblast as a Repair Cell during
Adult Liver Injury Response
Depending on the predominant tropism and the duration of the
injury, different patterns of liver inflammation are described.
First, two preferential tropisms of hepatitis can be separated
in theory: hepatitis with lobular tropism such as viral hepatitis
or hepatitis with portal tropism such as biliary obstruction
diseases. On light microscopy, a liver zone was preferentially
injured depending on the etiology but the other zone is
often involved. Two, with the duration and the severity of
the injury, the parenchyma architecture can become entirely
modified.
In case of acute hepatitis, liver morphology shows
inflammatory cell infiltration and hepatocellular damage.
The regression is characterized by macrophage cleaning of the
necrosis and regeneration. Gradually, these residual changes
fade and with times, the liver architecture returns to normal
(restitutio ad integrum). During this process, hepatic stellate
cell play a major role (Kordes et al., 2014). In addition,
after partial hepatectomy, incredible liver regeneration
capacities are obvious and hepatic stellate cell-derived
myofibroblasts can become progenitors, including epithelial
progenitors, participating in this specific property of the liver
(Swiderska-Syn et al., 2014).
In case of chronic hepatitis, the repetition and/or the
persistence of the injury lead to extensive involvement of the
inflammatory reaction in the organ. Then, a chronic scarring
process destroys the normal architecture of the organ leading
to fibrosis and finally cirrhosis. The scars are characterized
by extensive fibrous septa due to accumulation of collagenous
ECM. They surround regenerative nodules formed by hepatocyte
hyperplasia. Profound disturbance of the liver vascular bed
accompanying cirrhosis is characterized by venous thrombosis
and anarchic angiogenesis within the fibrous scars, sinusoid
remodeling and capillarization within the regenerative nodules
(Bosch, 2007). Myofibroblasts are the producers of the ECM
constituting the scars. But fibrosis is now not considered as a
static state, because it can be modified in structure or remodeled
in composition in regard to the extraordinary capacity of liver
regeneration (Schuppan et al., 2001). Depending on the stimulus,
myofibroblasts can contribute to fibrosis regression by releasing
of ECM degrading proteases.
Origin of the Myofibroblast Involved in
Adult Liver Repair Process
Depending on the duration of the injury, activated stromal cells
in acute inflammation and myofibroblasts in sub-acute/chronic
inflammation are recruited as a reaction to the lesion.
Local Production
Depending on the site of injury—portal, lobular or both—, the
corresponding stromal cells can be activated into myofibroblasts
(Figure 2).
Portal Fibroblasts
Fibroblasts maintain the connective tissue architecture via the
ECM that they secrete, but because they are a heterogeneous
population of connective tissue cells, they have specific functions
depending on their embryological origin and depending in fine
on their organic site (Rinn et al., 2006, 2008; Tschumperlin, 2013).
The fibroblasts located within the connective tissue of the portal
tract—the portal fibroblasts—give rise to portal myofibroblasts,
which are involved in portal fibrosis, notably in congenital biliary
malformations and acquired biliary diseases in human (Ozaki
et al., 2005) or after common bile duct ligation in animal models
(Tuchweber et al., 1996; Kinnman et al., 2003). It is well known
that hepatic stellate cells are also activated when the peripheral
lobular parenchyma is invaded by the inflammatory reaction
(Tuchweber et al., 1996; Kinnman and Housset, 2002). However,
data concerning the origin of the myofibroblasts during portal
fibrosis, i.e., hepatic stellate cells or portal fibroblasts, as well
as the kinetic of this cellular contribution are controversial: in
murine models, for Mederacke et al. (2013), hepatic stellate
cells are the principal providers at a late time point of the
injury, while it was not the case for Beaussier et al. (2007).
Nevertheless, portal fibroblasts and myofibroblasts definitively
have an important role in the biliary patterning. They participate
in the polarity maintenance and the proliferation regulation
of the cholangiocytes (Jhandier et al., 2005; He et al., 2008;
Tanimizu et al., 2012). In the same way, interactions between
myofibroblasts and biliary cells are also important in the ductular
reaction and fibrosis development during the chronic bile duct
diseases. In rat model of biliary fibrosis, reactive ductules express
growth factors such as platelet-derived growth factor, connective
tissue growth factor, or transforming growth factor-β2, which
activate portal fibroblasts and increase matrix deposition
(Milani et al., 1991; Grappone et al., 1999; Sedlaczek et al.,
2001). Accompanying these epithelial-mesenchymal interactions,
myofibroblasts produce tenascin and type IV collagen, which play
an important role in biliary development and activation (Terada
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FIGURE 2 | Schematic diagram of the various liver fibroblastic cells
able to acquire a myofibroblastic phenotype and involved in
fibrogenesis and tumoral stroma formation. The portal fibroblasts (PF)
located in the portal tract connective tissue around bile ducts (BD), portal
arteries (A), and portal veins (PV), and the second-layer cells (SLC), fibroblasts
located around the smooth muscle cells (SMC) and the endothelium (E) of
the centrolobular veins (CLV), can acquire a myofibroblastic phenotype, and
these cells do not seem to be able to reacquire a quiescent phenotype; in
contrast, the hepatic stellate cells (HSC) containing lipids droplets and
located in the Disse’s space between the hepatocytes (H) and the sinusoidal
endothelium (SE) can modulate their myofibroblastic differentiation, and
present pericyte-like features suggesting that they function as liver-specific
pericytes participating in the regulation of sinusoidal blood pressure.
Myofibroblasts (MF) present microfilament bundles and secrete large
amounts of extracellular matrix. In addition, PF and PF-derived MF are the
major, if not the only, cells that produce elastin. Numerous PF-derived MF are
involved in the formation of the abundant fibrous stroma present in
cholangiocarcinoma (CCC) while generally rare HSC-derived MF are present
in the scanty tumoral stroma of hepatocellular carcinoma (HCC) (Masson’s
trichrome histochemistry). C, collagen; EF, elastic fibers.
and Nakanuma, 1994; Lamireau et al., 1999). Portal fibroblasts
and myofibroblasts could be also involved in portal vasculature
and nerve development (for review, see Wells, 2014).
Hepatic Stellate Cells
Hepatic stellate cells, which account for about 5–8% of cells in the
normal liver, are characterized by a perisinusoidal distribution in
the Disse’s space and long processes extending along and around
sinusoids, between the hepatocyte plates (Lepreux et al., 2004).
The close association of hepatic stellate cells with endothelial cells
resembles that of pericytes in capillaries. However, in normal
liver, the endothelium is discontinuous and presents multiple
fenestrations without diaphragms, allowing the rapid transport
of solutes to the subendothelial space. In the normal liver, a basal
lamina-like structure separates the two cell types but there is no
true basement membrane. Hepatic stellate cells secrete collagens
but, contrary to portal fibroblasts, they seem to not produce
elastin (Lorena et al., 2004; Perepelyuk et al., 2013) even if, at
least in vitro, hepatic stellate cell-derived myofibroblasts secrete
tropoelastin into the culture medium (Kanta et al., 2002). On
activation, the hepatic stellate cells acquire a myofibroblastic
phenotype, contributing to the excessive ECM deposition
observed in the pathological conditions of fibrosis and cirrhosis.
Capillarization of the sinusoids also occurs, with a continuous
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endothelium formed, and the presence of a true basal lamina. The
experimental model of carbon tetrachloride (CCl4) treatment in
rats has been extensively used to study the involvement of hepatic
stellate cells in liver fibrogenesis (Sakaida, 2008). Following
chronic injury induced by CCl4 treatment, a large number of
myofibroblastic cells accumulate around centrolobular veins;
septa containingmyofibroblastic cells expressing α-SM actin then
develop between centrolobular areas, and large amounts of ECM
are deposited (Reeves and Friedman, 2002). Elastin and α-SM
actin are co-localized in septa developing after CCl4 treatment,
but activated α-SM actin-positive hepatic stellate cells in the
parenchyma do not contain elastin. Thus, in the CCl4 model,
the typical activated hepatic stellate cells containing α-SM actin
seem to play little or no part in elastin deposition (Lorena et al.,
2004). These observations suggest that different liver fibroblast
subpopulations are involved in deposition of the different ECM
components.
Others Cells
Other quiescent fibrocompetent cells can be activated into
myofibroblasts: vascular tunica media SM cells (Andrade
et al., 1999), second layer cells around the centrilobular veins
(Bhunchet and Wake, 1992), and capsular fibroblasts in the
Glisson’s capsule (Blanc et al., 2005). Recently, a process of
mesothelial-to-mesenchymal transition has been mentioned as
a novel source of myofibroblastic cells (for review, see Fausther
et al., 2013).
Epithelial-Mesenchymal Transition (EMT)
EMT defines a process in which epithelial cells acquire
mesenchymal features (Kalluri and Weinberg, 2009). EMT, as
well the reverse process of mesenchymal-epithelial transition,
occurs normally during the fetal development notably through
Hedgehog and Notch signaling pathways. The exploration
of Hedgehog signaling pathway in case of human or rat
liver fibrosis secondary to biliary obstruction showed that
cholangiocytes could undergo EMT (Omenetti et al., 2011).
Choi and Diehl (2009) have suggested that some quiescent
hepatic stellate cells are transitional cells which can differentiate
into epithelial cells or myofibroblasts. But, particularly in
this domain, the lack of specificity of lineage markers or
tracers, the kinetic of their expression and the fact that the
in vitro conditions do not reflect the in vivo situations, give
rise to conflicting results (for review, see Xie and Diehl,
2013).
Systemic Contribution
Some studies, particularly in advanced stages of fibrosis
and cirrhosis, have shown that myofibroblasts may
originate from bone marrow. For example, in a mouse
model of chronic alcohol consumption, bone marrow-
derived cells contribute to the development of α-SM actin
expressing cells (Fujimiya et al., 2009). However, the
real contribution of bone marrow-derived fibrocytes as a
source of myofibroblats during liver fibrosis and cirrhosis
remains a question of debates (Kisseleva and Brenner,
2012).
Myofibroblasts in Tumoral Stroma
Hepatocellular carcinomas (liver-cell carcinoma) have numerous
etiologies, notably chronic B and C virus infection or chronic
alcohol abuse and often, hepatocellular carcinomas arise in livers
showing cirrhosis, which is in itself a precancerous condition.
Bile-duct carcinomas (cholangiocarcinomas) are less common
than hepatocellular carcinomas.
During liver regeneration, myofibroblasts are involved in
regenerative response, but they are also implicated in the
tumoral stroma development (Lemoinne et al., 2013). These
myofibroblasts derive locally from hepatic stellate cells and/or
portal fibroblasts (Figure 2).
However, the nature of the tumoral stroma is totally different
in hepatocellular carcinoma and in cholangiocarcinoma.
In hepatocellular carcinoma, except in rare forms of scirrhous
or fibrolamellar hepatocellular carcinoma, tumoral stroma is
scanty. Often, the tumoral stroma is mixed with the fibrous
stroma of the surrounding cirrhosis. Interestingly, the vessels
surrounding the tumoral plates are not sinusoids, but continuous
capillaries with a true basement membrane. In contrast, in
cholangiocarcinoma, the tumoral cells are surrounded by an
abundant fibrous stroma containing numerous myofibroblasts
(Darby et al., 2011). This stroma is sclerous, sometimes with
calcification, may be extensive, and submerges the scanty tumoral
tubules.
We suggest that in hepatocellular carcinomas, mainly hepatic
stellate cells and SM cells (Lepreux et al., 2013) are involved
in the formation of the discrete tumoral stroma while, in
cholangiocarcinoma, essentially portal fibroblasts are responsible
for the large ECM deposition. Certainly, targeting cancer-
associated myofibroblats could be the key for optimal treatment
in future therapies and preventing or reversing the myofibroblast
activation could inhibit or at least reduce tumor growth (Rizvi
et al., 2014; Heindryckx and Gerwins, 2015).
Activation Spectrum of the Stromal Cells
(From Unactivated Stromal Cells to Mature
Myofibroblasts) and Reversibility of the
Myofibroblastic Differentiation
The phenomenon of stromal cell activation is related to the
transdifferentiation into myofibroblast. But, depending on the
intensity and the chronicity of the stimulus, stromal cells can
be activated at different degrees producing a spectrum from
cells showing mixed features of quiescence and activation
to cells presenting typical morphological and functional
characteristics of myofibroblasts. It is particularly true for the
hepatic stellate cells which can express overlapping features
during the progression from the quiescent state with for
example, the presence of vitamin A metabolism markers (intra-
cytoplasmic lipid droplets, vitamin A autofluorescence, cellular
retinol-binding protein-1 expression) to the fully activated state
with for example, the overexpression of α-SM actin and the
overproduction of ECM components (Ramadori, 1991; Gressner
and Bachem, 1995; Hautekeete and Geerts, 1997; Lepreux
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et al., 2001, 2004). From this point of view, hepatic stellate
cells present a more malleable phenotype compared with portal
fibroblasts. Indeed, differences have been reported between these
two fibrogenic cell populations, concerning the mechanisms
underlying myofibroblastic differentiation, activation, and
deactivation (Guyot et al., 2006). After isolation from healthy
rat liver and culturing under the same conditions, both hepatic
stellate cells and portal fibroblasts acquire a myofibroblast
phenotype. Hepatic stellate cell-derived myofibroblasts display
rounded and spread morphological characteristics with an
enlarged cytoplasm and, more important, a poor survival
after two to three passages. In contrast, portal fibroblasts-
derived myofibroblasts have more elongated morphological
characteristics and proliferate over multiple passages. In vivo,
during liver diseases, hepatic stellate cell- and portal fibroblast-
derived myofibroblasts present different fates. By using a
model of cultured precision-cut liver slices, the behavior of
the myofibroblast subpopulations during remodeling differs
depending on the experimental model, the pathological situation,
and the disease cause (Guyot et al., 2007, 2010). Hepatic stellate
cell-derived myofibroblasts can lose α-SM actin expression
without undergoing cell death, whereas in similar conditions,
portal fibroblast-derived myofibroblasts die by apoptosis. When
liver myofibroblasts are cultured on a basement membrane-like
substrate (Matrigel), they loss α-SM actin expression, reacquire
cytoplasmic lipid droplets, and thus revert, at least partly, to
quiescence (Sohara et al., 2002). In the mouse model of CCl4
induced liver fibrosis, although some myofibroblasts die by
apoptosis (Iredale et al., 1998), other myofibroblasts revert to
an inactive phenotype during regression of fibrosis (Kisseleva
et al., 2012). During the fetal liver portal tract maturation, a
same phenomenon of replacement of the myofibroblastic cells
by fibroblastic cells was observed (Villeneuve et al., 2009). These
data are in accordance with a relative plasticity of the stromal
cells; however, we suggest that this plasticity is well established in
hepatic stellate cell-derived myofibroblasts, knowing in addition
that hepatic stellate cells clearly present pericyte-like features
(Costa et al., 2001), whereas portal fibroblast differentiation
in myofibroblasts is more complete and less reversible. The
question of the regulation of the stromal cell activation is
important to consider therapeutic strategies. For example, the
blockage of Hedgehog or Notch signaling pathways in rodent
models of liver fibrosis leads to partial deactivation of activated
hepatic stellate cells and inhibition of fibrotic process (Chen
et al., 2012a,b; Xie et al., 2013).
Conclusion
In the past, many studies have been performed using cells derived
from explants of human liver parenchyma (Win et al., 1993).
Initially, it was suggested that mainly activation of hepatic stellate
cells contributes to this population. It is now assumed that these
cells are rather representative of many if not all the fibrogenic
cell populations present in the liver. It is also accepted that
these different fibrogenic cells present different features and that
their mechanisms of activation and deactivation are definitively
not identical. However, to our knowledge, no reliable markers
have been identified that allow unambiguous discrimination
between these different cell populations and particularly, between
hepatic stellate cell- and portal fibroblast-derived myofibroblasts.
However, clearly, depending on the cause of the lesion (e.g.,
virus, alcohol) and then the primary location of the injury,
the fibrogenic cells involved are different. Knowing that the
deactivation mechanisms of these different cells are not similar,
the question of the reversibility of the liver fibrosis/cirrhosis
remains a burning issue. Certainly, portal fibroblasts are involved
in many pathological situations and must be considered as a
major fibrogenic cell population beside the hepatic stellate cells.
Finally, the pivotal role of the portal (myo)fibroblasts in the
fetal liver development, as well as in wound healing, including
tumoral stroma which could be assimilated to an overhealing
wound (Schäfer and Werner, 2008), notably through their
interactions with the proliferative bile structures, would require
more investigations in the way of liver regeneration application.
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